Cybin

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.

Person,Hand,Harvesting,Psychedelic,Psilocybin,Mushrooms,Homemade,Or,Laboratory

Cannabis

Exclusives

CYBN

Federal support for psychedelics is rising fast. One biotech CEO explains what it means for clinical trials, access, and real-world therapy.

Psychedelics Policy Is Shifting In Washington: Here&#39;s What One Biotech CEO Sees Coming

Will,Psilocybin,Truffles,And,Magic,Mushrooms,Be,The,Future,For

Psychedelics

Politics

ATAI

CMPS

MNMD

PSIL

SEEL

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL &amp; more.

Ex-Gov&#39;t Foe Joins Trump, RFK Jr.&#39;s HHS To Lead Psychedelics Policy: What It Means For Investors

Detroit,,Mi,,Usa,,2021-05-29:,Beautiful,View,Of,Mgm,Grand

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BROS

COOP

CSCO

CYTK

HUBS

RDDT

MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday

Cybin Inc

Cyber Security 1 AB ADR

Press Releases

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

ALT5 Sigma

Bioage Labs

Biote

Canopy Growth Corporation - Common Shares

Canopy Growth

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

High Tide

MediWound

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Organigram Global

Omeros

Cassava Sciences

scPharmaceuticals

Third Harmonic Bio

Tvardi Therapeutics

Veru

Ventyx Biosciences

Guggenheim

HC Wainwright & Co.

Canaccord Genuity

Oppenheimer

EF Hutton

Comments

Cybin

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell